Fig. 6: Kaplan–Meier cumulative survival curve for health-related workforce exit after a PD diagnosis in workforce active persons that did or did not receive DAT during follow-up, as well as in non-PD controls.
From: Time to workforce exit after a Parkinson’s disease diagnosis
The median workforce survival was 101.0 (95% CI: 93.7–108.3) months in controls (events: 666, censored: 677), 64.0 (95% CI: 59.1–68.9) months in persons with PD and no DAT (events: 794, censored: 428), and 57.0 (95% CI: 51.3–62.7) months in persons with PD and DAT (events: 352, censored: 85). The survival distribution differed significantly in pairwise comparisons between the groups (log-rank tests, P < 0.001 except for DAT vs. no DAT: P = 0.012). Groups matched for age (±1 year) and sex to PD, DAT. The median age at diagnosis/matching was 55 ± 1 year. In the DAT group, the median time from diagnosis to DAT was 89 (1st–3rd quartile: 66–113.5) months. DAT includes subcutaneous apomorphine infusion, deep brain stimulation, and levodopa-carbidopa intestinal gel. PD Parkinson’s disease, DAT device-aided treatment, CI confidence interval.
